FHL2 is a multifunctional LIM domain protein that acts as a transcriptional modulator mediating proliferation and apoptosis in a tissue-specific manner. Upregulation of FHL2 has been detected in a variety of cancers. We demonstrate that upregulation of FHL2 is associated with a subset of acute myeloid leukemia with a characteristic gene-expression signature, and abnormalities of chromosome 5. In mice, expression of endogenous Fhl2 is downregulated coordinately during the differentiation of hematopoietic cells. Upregulation of FHL2 enhances proliferation of myeloid progenitor cells, and serialreplating efficiency of hematopoietic cells in vitro. Chimeric mice with enforced expression of FHL2 in bone marrow cells, are characterized by an expanded pool of myeloid progenitor cells, enhanced granulopoi esis and megakaryocytopoiesis. In addition, enhanced expression of FHL2 promotes cell-cycle entry of myeloid progenitor cells and increases the frequency of apoptosis of bone marrow cells in vivo. These results raise the possibility that deregulation of FHL2 contributes to the development of human myeloid disorders.
Introduction
Therapy-related myelodysplastic syndrome (t-MDS) or acute myeloid leukemia (t-AML) arises as a late complication of the treatment of malignant and nonmalignant diseases, and is a direct result of mutational events caused by cytotoxic chemotherapy, ionizing radiation or both. 1, 2 Recurring chromosomal abnormalities in t-MDS/t-AML include À7/del(7q), which has been associated with activating mutations of the RAS pathway and methylation silencing of the CDKN2B (p15INK4B) gene, and À5/del(5q), which is associated with TP53 mutations and a complex karyotype. To identify novel molecular pathways involved in the pathogenesis of t-MDS/t-AML, we previously performed gene expression profiling of CD34 þ hematopoietic progenitor cells (HPCs) from t-AML patients, and identified two major groups characterized by a À7/del(7q) or a normal karyotype (Group A), or À5/del(5q) (Group B). Patients with a À5/del(5q) have a unique expression pattern, characterized by an increased expression of genes involved in cell-cycle control (CCNA2, CCNE2, CDC2), checkpoints (BUB1) or growth (MYC), and loss of expression of ICSBP. 3 In addition, FHL2 is upregulated in this subgroup.
Human FHL2, originally known as DRAL, was first identified as a four and a half LIM-domain protein that was downregulated in rhabdomyosarcomas. 4 The LIM-domain consists of a 50-60 amino-acid cysteine-rich zinc-binding motif with the consensus sequence CX 2 CX 16À23 HX 2 -CX 2 CX 2 CX 16À21 CX(C,H,D), and is involved in protein-protein interactions. 5 FHL2 is a member of the subgroup of LIM-only proteins.
At present, little is known about the cellular function(s) of FHL2. FHL2 has been identified as a binding partner of a number of proteins, including hNP220, PS2, hCDC47, IGFBP-5 and a-and b-integrin subunits, suggesting that FHL2 is a multifunctional protein. 6 Furthermore, FHL2 functions as a cofactor for a number of transcription factors, including the androgen receptor (AR), AP-1, CREB, WT1, PLZF, b-catenin, SRF and RUNX2. 6 In mice, Fhl2 is predominantly expressed in the heart, but is not essential for cardiac development and function, because Fhl2-deficient mice have normal cardiac function. 7, 8 Recently, Fhl2 was shown to be involved in regulating the activity of osteoblasts in vivo. 9 However, the role of FHL2 in hematopoiesis, and whether deregulation of FHL2 in vivo contributes to the pathogenesis of hematological malignant diseases, is unknown.
In this study, we demonstrate that FHL2 is overexpressed in a subset of AML and t-AML. Moreover, overexpression of FHL2 in bone marrow (BM) cells in a mouse model enhances proliferation of myeloid progenitor cells, granulopoiesis and megakaryocytopoiesis, and promotes apoptosis in vivo.
Materials and methods

RNA isolation and real-time RT-PCR
Total RNA was extracted from CD34 þ cells isolated from t-AML patients or normal CD34 þ cells purchased from Cambrex (East Rutherford, NJ, USA). 3 Total RNA (2-5 mg) was used to produce single-strand cDNA by reverse transcription using a T7-(dT)24 primer and Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time RT-PCR was performed using the LightCycler System (Roche, Indianapolis, IN, USA) as described previously. 3 RT-PCR analysis of human FHL2 was performed using the 5 0 -primer (GCCAACACCTGCGAGGAGT) and 3 0 -primer (AGTGCCGGTCCTTGTAAGACA), with or without the Taqman probe (CCCATCGGCTGTGACTGCAAGGA) containing a 5 0 FAM reporter and a 3 0 TAMRA quencher (Synthegen, Houston, TX, USA). RT-PCR analysis of mouse Fhl2 was performed using the 5 0 -primer (AGTTTCCATACTGCCTGACCTGCT) and 3 0 -primer (ACTTTGTGCCACCCAGACCACTAA).
Retroviral vectors
A 0.84 kb, N-terminal FLAG-tagged human FHL2 transcript was amplified by PCR from BM cDNA, subcloned into the Topo-TA cloning vector (Invitrogen) and confirmed by DNA sequencing. XhoI and BglII restriction sites were added to the 5 0 and 3 0 ends of the FHL2 transcript, respectively, by PCR. The FLAG-FHL2 cassette was isolated as a XhoI-EcoRI fragment, or a XhoI-BglII fragment from the Topo-TA cloning vector, and subsequently cloned into the MSCV-IRES-EGFP (MIGR1) vector, or MSCV-PGK-EYFP vector, respectively. The MSCV-PGK-EYFP vector was kindly provided by Dr Guy Sauvageau (University of Montreal, Canada).
Retroviral infection
High-titer retrovirus was produced by transient transfection of 293 T cells with the pCL ecotropic packaging plasmid 10 and the appropriate retroviral vectors using Effectene Transfection Reagent (QIAGEN, Valencia, CA, USA). BM cells were collected from mice injected intravenously 4-5 days previously with 5-Fluorouracil (5-FU; 150 mg/kg), and cultured in a Petri dish for 24-48 h in Iscove's minimal essential media with 15% fetal bovine serum 10 ng/ml of human interleukin (IL)-6, 10 ng/ml of murine IL-3 and 100 ng/ml of murine stem cell factor (PharMingen, San Diego, CA, USA). Subsequently, the BM cells were infected with the appropriate retrovirus by spinoculation as described previously.
11 EGFP þ cells were sorted 2-3 days after retroviral infection.
Animals and bone marrow transplantation
C57BL/6 or Balb/c male mice (4-6 weeks old) were used as BM donors; female C57BL/6 mice or Balb/c (6-10 weeks old) were used as BM recipients. All mice were obtained from Taconic (Hudson, NY, USA). The recipient mice received a lethal dose of irradiation (960 rad) from a Cs source. After 3-4 h, the mice were administered B0.4-1.0 Â 10 6 retrovirally-infected BM cells by retroorbital or tail vein injection.
In vitro clonogenic progenitor and serial-replating assays
Freshly transduced EGFP þ BM cells, or EYFP þ BM cells from primary transplant chimeras killed 12-14 weeks after transplantation were sorted using a MoFlo-HTS (Dakocytomation, Ft. Collins, CO, USA), and then plated in M3434-media (StemCell Technologies, Vancouver, BC, Canada) following the manufacturer's instructions. For replating assays, all colonies from primary plates were pooled after 8-9 days of incubation, and were subsequently replated in M3434-media containing 10 ng/ml of human IL-6, 10 ng/ml of murine IL-3 and 100 ng/ml of murine stem cell factor.
Flow cytometry
Single-cell suspensions of spleen (SP), thymus, BM and peripheral blood (PB) were stained with the indicated antibodies conjugated with phycoerythrin (PE), allophycocyanin (APC) or biotin. Biotinylated antibodies were then stained with streptavidin-PE. Flow cytometric analysis of mature hematopoietic cells, and isolation of hematopoietic stem cells (HSCs) and HPCs was performed as described previously. 12 For sorting of HSCs and HPCs, BM cells were stained with biotinylated rat antibodies specific for lineage markers (CD3, B220, IgM, Ter119, Mac-1, Gr-1 and CD19). The Lin þ cells were depleted with sheep anti-rat immunoglobulin G-conjugated magnetic beads (Dynabeads M-450), and the remaining cells were resuspended and stained with APC-c-Kit, PE-Sca-1, PE-Cy5-Flk2 (Flt3) and streptavidin-FITC for HSCs, stained with APC-cKit, PE-Sca-1, PE-Cy5-IL-7R and streptavidin-FITC for common lymphoid progenitor cells (CLPs), or stained with APC-c-Kit, PESca-1, FITC-CD34, PE-Cy7-CD16/32 (Fcr) and streptavidin-PECy5 for myeloid progenitors. Dead cells were excluded by DAPI or propidium iodide staining. FACS analysis was performed on a FACSCanto flow cytometer (BD BioScience, San Jose, CA, USA) using FlowJo (Tree Star, Stanford, CA, USA) software. To detect apoptotic cells, we used Annexin V-PE and 7-ADD staining (PharMingen).
Western blot analysis
Cell extracts were prepared using lysis buffer containing 1% Triton X-100, 100 mM NaCl, 10% glycerol, 50 mM Tris-HCl, 2 mM EDTA, and proteinase inhibitor cocktail (EMD Biosciences, San Diego, CA, USA). Western blot analysis was performed as described previously. 13 
Results
Deregulation of FHL2 is associated with a distinct subset of t-AML and AML To identify novel molecular pathways involved in the pathogenesis of t-AML, we previously performed expression-profiling analysis of CD34 þ early-stage progenitor cells from t-AML patients (n ¼ 14) and healthy individuals (n ¼ 3) using Affymetrix U95A human oligo chips. 3 This analysis revealed that FHL2 is upregulated in CD34 þ hematopoietic cells from patients with a À5/del(5q) (Group B; Figures 1a and c). The expression data from microarray analysis was confirmed by a real-time RT-PCR assay ( Figure 1a ). To determine whether FHL2 is also deregulated in patients with AML de novo, the expressionprofiling data of 285 AML patients 14 was analyzed for the expression of FHL2. Over 10% of the cases showed a significantly higher expression level of FHL2; most of these patients were classified into subgroups 7 and 8 ( Figure 1b) , comprising 31 patients without consistent cytogenetic abnormalities. In addition, we performed an analysis of the Affymetrix GeneChip dataset for 170 AML patients published online (http://gedp.nci.nih.gov/dc/index.jsp:experiment accession ID: 757) by Wilson et al. Six clusters of patients were identified based on strong similarities in gene expression among the 9463 genes. 15 Cluster B includes 22 patients, with a gene expression profile most similar to subgroups 7 and 8 identified by Valk et al., 14 and was characterized by an increased expression of FHL2 as compared to 30 randomly selected AML patients ( Figure 1c ). Cluster B AML patients had the highest rate of resistant disease and the lowest survival rate among the patients analyzed. 15 Taken together, these data suggest that FHL2 is frequently deregulated in AML, and that most of these patients have a similar characteristic gene expression signature. Moreover, the average expression of FHL2 is increased B2.8-fold in those patients with abnormalities of chromosome 5 (8/170 patients) as compared to 30 randomly selected AML patients (Figure 1c ), indicating that upregulation of FHL2 is associated with abnormalities of chromosome 5 in both t-AML and AML de novo.
Fhl2 is expressed by subsets of hematopoietic progenitor cells
To begin to understand the role of endogenous Fhl2 in hematopoiesis, we employed real-time quantitative RT-PCR (qRT-PCR) to examine the relative expression of Fhl2 in purified murine stem cells, progenitor cells and mature hematopoietic cells. Fhl2 is expressed in all subsets of HPCs, and in some subsets of mature hematopoietic cells ( Figure 2 ). In progenitor cells, the expression of Fhl2 is higher in CLPs, than in HSCs, 
, and the expression of Fhl2 is barely detected among myeloid
. This data suggests that Fhl2 is downregulated during the differentiation of B cells and myeloid cells.
Overexpression of FHL2 enhances proliferation and replating capacity of hematopoietic stem/progenitor cells in vitro As FHL2 is upregulated in leukemia cells from a subset of AML patients, we examined the effects of FHL2 overexpression in clonogenic progenitor cells in vitro. The murine stem cell virusbased retroviral vector, MIGR1, which coexpresses EGFP, was used to express FLAG-FHL2 in primary BM cells isolated from 5-FU-treated C57BL/6 mice. Transduction efficiencies in primary BM cells ranged from 30-70% for both FHL2-expressing virus and control virus (Figure 3a) . The expression of full-length FHL2 from the retroviral vector was confirmed by western blot analysis with anti-FLAG antibody (Figure 3b ).
GFP
þ BM cells were sorted and cultured in methylcellulose media. MIGR1-FHL2-infected BM cells gave rise to B50% more colonies than that observed in control cultures containing vector-infected cells (Figure 3c ). Of note is that MIGR1-FHL2-transduced cells did not give rise to colonies in the absence of exogenous growth factors (data not shown), indicating that FHL2 overexpression did not confer growth factor independence. In serial-replating assays, MIGR1-FHL2-transduced, GFP þ , Lin À cells gave rise to B50% more colonies than the MIGR1-transduced Lin-cells at the first plating; the size of the colonies was comparable. This is consistent with the results we obtained using whole BM cells. At the second plating, MIGR1-FHL2-transduced Lin À cells formed larger colonies, as well as a greater number of colonies, as compared to MIGR1-transduced Lin À cells (Figures 3d and e) . However, the morphology of MIGR1-transduced and MIGR1-FHL2-transduced cells from these colonies is similar (Supplementary Figure 1) . At the third plating, control cells lost their potential to form colonies, whereas replating of MIGR1-FHL2-transduced Lin À cells leads to formation of colonies, indicating that overexpression of FHL2 enhances replating-efficiency of hematopoietic stem/progenitor cells in vitro. 
FHL2 enhances myelopoiesis
To recapitulate the upregulation of FHL2 observed in CD34 þ enriched BM cells from patients with t-AML or AML de novo, we generated cohorts of BM chimeras in both C57BL/6 and BALB/c genetic backgrounds by overexpressing human FHL2 in BM cells by retroviral transduction, followed by transplantation (note that FHL2 is conserved between human and mouse with 91% amino-acid identity). 16 To generate chimeric C57BL/6 mice, B1 Â 10 6 total BM cells, infected with MSCV-EYFP or MSCV-FHL2-EYFP by spinoculation, were transplanted into lethally-irradiated mice. The transduction efficiency (EYFP þ cells) for both retroviruses is B38%. At 12 weeks posttransplantation, EYFP þ cells were detected in single-cell suspensions from BM, SP and thymus from both MSCV-EYFP-and MSCV-EYFP-FHL2-expressing mice (Supplementary Figure 2a) , indicating that MSCV-EYFP-FHL2-transduced primitive hematopoietic cells are able to repopulate blood cell lineages in recipient mice. In addition, expression of the FLAG-FHL2 protein was confirmed by western blot analysis in BM, SP and thymus from MSCV-EYFP-FHL2 mice, but not from MSCV-EYFP mice (Supplementary Figure 2b) . The expression of human FHL2 from the retroviral vector is significantly higher than the expression level of endogenous mouse Fhl2 in HPCs from MSCV-EYFP-FHL2 mice (Supplementary Figure 3) . The recipient mice were transplanted with the same number of total BM cells with B38% EYFP þ or EYFP-FHL2 þ cells; however, at 5 weeks posttransplantation, the frequency of EYFP þ PB cells from MSCV-EYFP-FHL2 (n ¼ 9) mice was significantly lower than that of MSCV-EYFP (n ¼ 9) mice (28±17.4 vs 47.9±13.9%, Po0.001; Supplementary Figure 4 
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PB from EYFP-FHL2 mice as compared to control EYFP mice (Supplementary Figure 5) . In addition, we found that the total number of BM cells and SP cells are comparable in both EYFPand EYFP-FHL2-mice (Supplementary Figure 6A, Figure 6A, B) . However, the total number of EYFP þ myeloid cells is comparable in BM and SP from both chimeric mice (Supplementary Figure 6A , B). These data suggest that overexpression leads to relative expansion of myeloid cells, but does not affect the B-lymphoid cells. Consistent with the increase in mature myeloid cells, the Lin lo , c-Kit þ progenitor-enriched population is expanded B2.5-fold in EYFP þ BM cells from MSCV-EYFP-FHL2-transduced mice as compared to control mice (2.3 ± 0.92 vs 0.94±0.83%; n ¼ 5, Po0.05; Figure 4c ). In addition, the EYFP þ BM cells isolated from the EYFP-FHL2-mice gave rise to B70% more colony-forming cell (CFC) colonies as compared to Figure 4d ). This elevation is largely due to an increase in the number of colony-forming unit-granulocyte-macrophage colonies (Figure 4d) .
In a separate experiment, cohorts of chimeric BALB/c mice expressing FHL2 or EYFP were generated, and examined over a 10-month period by analyzing the complete blood counts, and blood smears. Both MSCV-EYFP and MSCV-EYFP-FHL2 mice had normal WBC, RBC, neutrophil, lymphocyte and platelet counts (Supplementary Figure 7) . By examining the BM smears, and H&E-stained sections of SP and liver, we found that none of the chimeric mice developed a myeloproliferative disease or leukemia by 11 months posttransplantation, indicating that overexpression of FHL2 is not sufficient to induce leukemia or that a long latency is required for induction of leukemia by upregulation of FHL2 (Supplementary Figure 8) . Consistent with the phenotypes observed in C57BL/6 mice, overexpression of FHL2 in BALB/c mice enhances granulopoiesis significantly (Supplementary Figure 9) . In addition, we found that the CD41 þ population representing megakaryocytes is increased in BM, suggesting that megakaryocytopoiesis is enhanced by overexpression of FHL2 (Figure 4b, middle panel) . The developmental stages of erythroid precursors can be defined by the expression of the Ter119 and CD71 cell-surface markers. 17 Flow cytometric data revealed that FHL2 chimeric mice had a normal distribution of erythroblasts in SP as compared to EYFP mice (Figure 4b, bottom panel) . Although the percentage of early erythroblasts (Ter119 low , CD71 þ ) in these mice is variable, there was no statistical difference in early erythroblasts between MSCV-EYFP and MSCV-EYFP-FHL2-mice (0.29 ± 0.23 vs 0.23±0.11; n ¼ 4, P ¼ 0.7).
Overexpression of FHL2 promotes cell-cycle entry of myeloid progenitor cells and increases apoptosis of bone marrow cells in vivo
In vitro colony-forming assays showed that FHL2-transduced myeloid progenitor cells had increased proliferative capacity. To determine if FHL2 overexpression promotes progression of the cell cycle in vivo, we analyzed the cell-cycle status of myeloid progenitor cells in chimeric FHL2 and EYFP mice. The increased proportion of myeloid progenitor cells in S-phase indicates that upregulation of FHL2 enhances the proliferation of myeloid progenitor cells in vivo (Figure 5a ). Ectopic FHL2 expression in COS-1, RD and NIH3T3 cells induces apoptosis, and transcription of FHL2 is induced by p53 in response to g-irradiation. Figures 4 and 6 ).
Discussion
The FHL2 LIM domain protein is a multifunctional modulator that regulates proliferation and apoptosis in a tissue-specific manner. In this study, we analyzed the role of FHL2 in hematopoiesis. Analysis of the expression of endogenous Fhl2 in subpopulations of progenitor cells and mature hematopoietic cells revealed that Fhl2 is expressed in all subsets of progenitor cells at relatively high levels, whereas Fhl2 expression is very low or undetectable in mature populations of hematopoietic cells. This data suggests that Fhl2 plays a role in the function of progenitor cells, and that downregulation of Fhl2 is either necessary for, or the consequence of, the differentiation of HPCs during normal hematopoiesis. FHL2 acts as a coactivator or corepressor for multiple transcription factors, including PLZF, b-catenin and WT1, 6 each of which has been implicated in hematopoiesis and leukemogenesis. Whether the function of FHL2 in hematopoiesis is mediated by one of these transcription factors remains to be determined.
In vitro CFC and serial-replating assays revealed that overexpression of FHL2 enhances the proliferation of myeloid progenitor cells in vitro. To determine if enhanced expression of FHL2 disrupts normal hematopoiesis, and leads to the development of leukemia, we generated a murine model with FHL2 overexpression in BM cells by retroviral transduction and transplantation. By characterization of the chimeric mice, we found that the proportion of mature myeloid cells (Gr-1 þ , 
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Mac-1 þ ) and megakaryocytic cells (CD41 þ ) was increased significantly in FHL2 chimeric mice, whereas B cells (B220 þ ) were not affected. However, the distribution of erythroid blast cells in SP was unchanged. These data suggested that overexpression of FHL2 in vivo enhances granulopoiesis and megakaryocytopoiesis, but does not affect differentiation of the B cell and erythroid lineages. Consistent with the observation that the progenitor cell pool is expanded in FHL2 chimeric mice, FHL2-expressing cells isolated from the recipient mice contained more CFCs than the vector-transduced BM cells. Furthermore, analysis of the cell-cycle profile indicated that the proportion of S-phase cells is increased in myeloid progenitor cells from FHL2 chimeric mice as compared to control chimeric mice. Taken together, these results suggest that overexpression of FHL2 leads to an increase in the progenitor cell pool, as a result of higher proliferative activity of progenitor cells. Recent studies have demonstrated that FHL2 regulates cell proliferation by controlling the expression of critical cell-cycle regulators. Fhl2 is a direct transcriptional regulator of Ccnd1, and regulates cell proliferation of murine fibroblast cells by controlling the expression of Ccnd1.
18 FHL2 inhibits the antiproliferative activity of E4F1, a key player in the control of somatic cell proliferation and survival, 19 and regulates the expression of CDKN1A in breast cancer cells. 20 Whether the function of FHL2 in regulating the proliferation of myeloid progenitor cells is mediated by these cell-cycle regulators remains to be determined.
Previous data indicate that FHL2 acts as a proapoptotic protein in a variety of cell lines; 16 however, the mechanism for this phenomenon is poorly understood. Here, we demonstrate that enforced expression of FHL2 does not induce apoptosis of primary hematopoietic cells in the presence of SCF/IL3/IL6. As the microenvironment of hematopoietic stem/progenitor cells in vivo differs from in vitro conditions, we also assessed apoptosis of HPCs from recipient mice transplanted with FHL2-expressing cells. Enhanced expression of FHL2 increases the proliferative activity of myeloid progenitor cells, but is accompanied by an increased frequency of apoptosis. Elevated apoptosis may occur as a result of deregulated hematopoiesis, for example, in the early stages of MDS before progression to AML. 21 Our mouse model with overexpression of FHL2 is a potential model to examine this cellular phenomenon.
Given its role in regulating critical cellular processes, such as proliferation and apoptosis, it is not surprising that FHL2 has been implicated in tumorigenesis. For example, FHL2 is markedly upregulated in hepatoblastomas 22 and ovarian carcinomas. 23 In prostate cancer, stimulation of the Rho signaling pathway by extracellular stimuli induces translocation of FHL2 to the nucleus, and correlates with progression to a more malignant phenotype. 24 In this study, we demonstrate that a subgroup of t-AML is characterized by overexpression of FHL2, and abnormalities of chromosome 5. Moreover, FHL2 overexpression defines a subset of AML de novo. Taken together, these observations suggest that FHL2 is an oncogene. It is possible that the oncogenic potential of FHL2 in hematopoietic cells is masked by apoptosis, analogous to the MYC oncoprotein, a potent inducer of apoptosis. 25 In a transgenic model with expression of a switchable form of the Myc protein, Myc activation induces proliferation in adult pancreatic b-cells in vivo, but this is overwhelmed by apoptosis, ultimately leading to complete ablation of b-cells. However, suppression of b-cell apoptosis by coexpression of Bcl-X L in this model induces rapid tumor progression. 26 t-AML with abnormalities of chromosome 5 is characterized by a high frequency of TP53 mutations. 1 Thus, if FHL2 contributes to leukemogenesis, it is likely to occur in the context of cooperating mutations, which enhance survival. In summary, we have demonstrated that the transcriptional modulator, FHL2, is overexpressed in a subset of AML de novo and t-AML. Moreover, overexpression of FHL2 in BM cells in a mouse model enhances proliferation of myeloid progenitor cells, granulopoiesis and megakaryocytopoiesis, and promotes apoptosis in vivo, raising the possibility that deregulation of FHL2 contributes to the development of human myeloid disorders.
